David Kalinowski, President of competitive intelligence services firm Proactive Worldwide, Inc., to conduct a full-day workshop at the 33rd Annual SCIP International Conference in Orlando.

SCHAUMBURG, Ill. (PRWEB) May 11, 2018

President David Kalinowski of global strategic Intelligence firm Proactive Worldwide, Inc. will facilitate a full-day workshop that shares best practices in developing evidence-based competitive intelligence programs. PWW’s session, “CI100: Foundations of Competitive Intelligence,” will be held at the 33rd Annual SCIP International Conference and Exhibition in Orlando during May 14-17, 2018.

SCIP (Strategic and Competitive Intelligence Professionals) offers several programs during the calendar year at multiple locations, providing training to hone skills and sharing innovations on the horizon within the industry to working practitioners. This introductory workshop is designed for those new to the field as well as for those desiring a refresher course on the fundamentals of building a corporate intelligence capability in a changing marketplace.

Kalinowski stated he shares a commitment to furthering industry goals and is excited for these opportunities do his part in better preparing today’s professionals for success in the competitive intelligence profession. Kalinowski is a recipient of the organization’s Catalyst Award and Distinguished Member—Solutions Provider Award, and has played an active role within SCIP’s continual education series for many years.

SCIP is calling this year’s conference “Next Generation Intelligence,” which includes educational programs for today’s intelligence environment that demands greater anticipatory and predictive skill, faster analysis, a higher standard of evidence, and organizational agility. For more information or to register for this event, visit https://www.scip2018international.com/.

About Proactive Worldwide, Inc.
Proactive Worldwide, Inc. is a global research and strategic intelligence consulting firm that provides evidence-based, constructive information within the competitive intelligence, market intelligence, and customer insights domains. Anchored by primary source research for over 22 years, Proactive’s multilingual professionals assist our clients with offerings that include but are not limited to competitive research services, competitor assessments, market entry and defense strategies, war gaming workshops and scenario planning events, and customer experience and user experience studies. To learn more, visit http://www.proactiveworldwide.com Reported by PRWeb 3 hours ago.

PARSIPPANY, N.J., May 11, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, announced today that it will host a live conference call and webcast at 8:30 a.m. Eastern Time on May 15 to discuss the company’s financial results and business progress to date. *Date and Time: *May 15, 2018, 8:30 a.m. ET
*US Telephone: *1-877-407-6184
*International Telephone: *1-201-389-0877
*Webcast: *http://www.audio-webcast.com/cgi-bin/visitors.ssp?fn=visitor&id=5607

All listeners should confirm they are dialing in for the Interpace Diagnostics conference call with the operator who will promptly place them into the call. A webcast replay will be available on the company’s website (www.interpacediagnostics.com) approximately two hours following completion of the call and will be archived on the company’s website for 90 days.

*About Interpace Diagnostics Group, Inc.*
Interpace is a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The Company currently has four commercialized molecular tests and one test in a clinical evaluation process (CEP); PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX® for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR® for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX™, that differentiates lung cancer of primary vs. metastatic origin. BarreGEN®, for Barrett's Esophagus, is currently being “soft launched” with key opinion leaders as we continue to gather data on this assay that will assist us in seeking favorable reimbursement as well as important clinical information. Barrett's Esophagus is a rapidly growing diagnosis that affects over three million people in the US, and over time can progress to esophageal cancer. The Company’s data base includes data from over 45,000 patients who have been tested using the Company’s current products, including over 15,000 molecular tests for thyroid nodules. Interpace has been designated by CIO Applications magazine as one of the top 20 companies for providing bioinformatics solutions. Interpace’s mission is to provide personalized medicine through molecular diagnostics, innovation and data to advance patient care based on rigorous science. For more information, please visit Interpace’s website at www.interpacediagnostics.com

*Forward Looking Statements*

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company's future financial and operating performance, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, the Company’s history of losses, the Company's ability to adequately finance the business, the market's acceptance of its molecular diagnostic tests, its ability to retain or secure reimbursement, its ability to secure additional business and generate higher profit margins through sales of its molecular diagnostic tests, in-licensing or other means, projections of future revenues, growth, gross profit and anticipated internal rate of return on investments and its ability to maintain its NASDAQ listing. Additionally, all forward-looking statements are subject to the “Risk Factors” detailed from time to time in the Company's SEC filings, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed on March 23, 2018, Quarterly Reports on Form 10-Q and other SEC filings. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

CONTACTS:

Interpace Diagnostics
Investor Relations
Joseph Green / Andrew Gibson
646-653-7030 / 7719
jgreen@edisongroup.com/ agibson@edisongroup.com Reported by GlobeNewswire 2 hours ago.

EEStor Materials Expected to Allow Licensees to Produce Smaller and Cheaper Capacitors

TORONTO and AUSTIN, Texas, May 11, 2018 (GLOBE NEWSWIRE) -- EEStor Corporation (TSX-V:ESU) (“EEStor” or the “Company”) has developed a hybrid capacitor dielectric material (glass-CMBT) that is shown in independent third party testing to provide higher permittivity at a significantly reduced cost to existing capacitor technologies, and is anticipated to benefit the US$2.3 billion plastic film capacitor industry. Licensees of the technology would have access to these proprietary materials to manufacture capacitors for the next generation infrastructure, power supply, propulsion, wind, solar, wave and geothermal energy markets. Market Research Future projects the global film capacitor market to increase to US$2.7 billion by 2023.Ceramic capacitors produced using EEStor materials have the same capacitance as commercially available plastic film capacitors, yet are up to 92 percent smaller. A reduction in size translates to a reduction in cost as less raw material is required for manufacturing and ceramic dielectric materials are less expensive than metallized plastic film to produce. Independent testing found that material costs were up to 1,195% more for commercial film capacitors than for the EEStor CMBT-glass capacitors.^1

According to EEStor Founder and CEO Ian Clifford, “We expect the development of this new dielectric material to revolutionize the pricing structure of the green energy market and give licensees of our technology a significant competitive advantage in producing materials for the emerging high-tech economy.”

Film capacitors are used in power grid distribution systems, the green energy sector in solar, wind, and wave energy generation systems, and in electric and hybrid vehicles. EEStor has published a Market Report outlining the key benefits of its technology in these emerging renewable markets.

EEStor is in the process of establishing licensee relationships to pursue multiple vertical market opportunities. Licensees will gain access to EEStor’s intellectual property for the purpose of designing and building commercial capacitors using EEStor’s patented CMBT dielectrics and its associated manufacturing and assembly know-how and expertise.

EEStor has tested its capacitors made of Composite Modified Barium Titanate (CMBT) dielectric materials extensively using three independent companies - Intertek, Radiant Technologies and MRA Laboratories. Additional testing was conducted in side-by-side comparisons of competitive products and confirmed the findings of the reduced size and cost of EEStor capacitors.

*About EEStor *
EEStor is a developer of high energy density solid-state capacitor technology utilizing the Company’s patented Composition Modified Barium Titanate (CMBT) material. The Company is focused on licensing opportunities for its technology across a broad spectrum of industries and applications.

The Company’s success depends on the commercialization of its technology. There is no assurance that EEStor will be successful in the completion of the various enhancement phases underway to warrant the anticipated licensing opportunities in the technology. Readers are directed to the "Risk Factors" disclosed in the Company’s public filings.

*For additional information please contact:*

Ian Clifford
Chief Executive Officer
EEStor Corporation
Tel. 416-535-8395 ext. 3
ian.clifford@eestorcorp.com 

Mark Olson
Senior Vice President
Sparkpr
Tel. 512-507-1993
mark.olson@sparkpr.com
           
*Forward-looking Statements*

Certain statements and documents referred to in this release, other than statements of historical fact, may include forward-looking information that involves various risks and uncertainties that face the Company; such statements may contain such words as "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions, and may be based on management's current assumptions and expectations related to all aspects of the power and energy storage industries, consumer demand for energy storage products and solutions and the global economy. Risks and uncertainties that may face the Company include, but are not restricted to: EEStor may not be able to replicate test results in mass produced commercial products; the EEStor capacitor and energy storage technology may not be successfully commercialized at all, in a manner providing the features and benefits expected while under development, or on a timely basis or the Company may not be able to successfully incorporate this technology into its current or proposed products or the products of others; steps taken by the Company to protect its proprietary rights may not be adequate or third parties may infringe or misappropriate the Company's proprietary rights; the Company has a history of losses from operations and may not be able to obtain financing, if and when required or on acceptable terms due to market conditions or other factors, to fund future expenditures for general administrative activities, including sales and marketing and research and development, expansion, strategic acquisitions or investment opportunities or to respond to competitive pressures; competitors may develop products which offer greater benefits to consumers, have greater market appeal or are more competitively priced than those offered by the Company; the Company may be exposed to product liability claims which exceed insurance policy limits; the Company is dependent on the ability and experience of a relatively small number of key personnel; new products introduced by the Company may not be accepted in the market or to the extent projected; new laws and regulations may be enacted or existing ones may be applied or governmental action may be taken in a manner which could limit or curtail the production or sale of the Company's products; and the Company may be negatively affected by reduced consumer spending due to the uncertainty of economic and geopolitical conditions.

These risks and uncertainties may cause actual results to differ from information contained in this release, when estimates and assumptions have been used to measure and report results. There can be no assurance that any statements of forward-looking information contained in this release will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements.

These and all subsequent written and oral statements containing forward-looking information are based on the estimates and opinions of management on the dates they are made and expressly qualified in their entirety by this notice. Except as required by applicable laws, the Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change. Readers are cautioned not to place undue reliance on any statements of forward looking information that speak only as of the date of this release. Additional information identifying risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's filings with the various Canadian securities regulators which are available online at www.sedar.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

___________________________^1Understanding the Global Market for Aluminum Electrolytic Capacitors, Dennis M. Zogbi  Reported by GlobeNewswire 2 hours ago.

Reported by SeekingAlpha 2 hours ago.

With five certain byelections and a possible general election this year, Australian voters face the starkest choice over economic policy in a generation. Reported by Brisbane Times 50 minutes ago.

Inflight Wi-Fi is one of several improvements in Spirit’s commitment to Invest in the Guest

MIRAMAR, Fla., May 11, 2018 (GLOBE NEWSWIRE) --  Guests on Spirit Airlines will soon be able to watch, stream, surf and text from 30,000 feet. Spirit Airlines is signing an agreement today to install Wi-Fi on all of its planes by summer 2019, giving even more options to Guests to enhance their inflight experience. Spirit operates the newest aircraft fleet in the country, our Fit Fleet^®, and will also become the first ultra-low cost carrier in the Americas to offer Wi-Fi. 

“We’re thrilled to enhance the inflight Guest experience with the addition of new-generation Wi-Fi,” said Ted Christie, Spirit Airline’s President. “By next summer, every plane in our fleet should be fully equipped to keep our Guests connected in the skies. It’s just one of the many investments we’ve made and will continue to make for our Guests.”

Spirit Airlines Wi-Fi technology partner, Thales Group, a global technology leader for decisive moments in aerospace, defense and security, and transportation markets, is bringing the high-end Ka-band HTS (High Throughput Satellite) system onboard the aircraft. The technology will bring Spirit Guests high-speed web browsing and streaming experiences similar to what they would find at home. In 2021, the state-of-the-art technology will get even better, with the launch of SES-17, a new satellite operated by SES and built by Thales Alenia Space, which will increase speeds and coverage to an unprecedented level in the industry. Spirit Wi-Fi is projected to provide service coverage immediately for 97% of Spirit’s routes upon entry into service.

“Thales is proud to be partnering with Spirit to mark a new era of Guest experience in connectivity and bring solutions that make tomorrow possible today,” said Dominique Giannoni, CEO of Thales InFlyt Experience. “We are focused on supporting Spirit’s mission and helping to shape new opportunities as we work together to provide an exceptional passenger experience.”

Spirit will offer high-speed web browsing and streaming options starting with an average price of $6.50, with a cost range expected to be lower or higher based on the route and demand. 

*Spirit’s Commitment to Invest in the Guest*
Spirit Wi-Fi is one of many improvements coming up for the airline, as part of its pledge to keep improving and Invest in the Guest.

“We understand that flying for as little money as possible is only part of our promise,” said Christie. “We promise to go further. We’ll continue to listen to our Guests, and they’ll continue to see our dedication to improving service for them. We’ll keep adding exciting new destinations, improving our check-in process, frequent flier program and inflight experience, as well as continuing to dedicate ourselves to give back to the communities where we live and work.”

Christie introduced Spirit’s Invest in the Guest pledge with the announcement of Wi-Fi installation.

“Our promise is to keep going, to keep improving, and to invest in our Guests,” said Christie as part of the pledge. “We intend to improve our Guests’ experience every chance we get.”

A video message by Spirit Airlines President Ted Christie delivering the Guest pledge, information on improvements made by Spirit, commitments to Guests, and future initiatives can be found at InvestInTheGuest.com.

Spirit wants to hear directly from Guests about new ways to keep improving. Guests who share their thoughts or requests at InvestInTheGuest.com will be entered to win free round-trip tickets.

*Spirit Airlines’ Guest Commitments*
Spirit Airlines is committed to improving the Guest experience and unveiled the following Guest commitments:

*• Performance Promise* – The commitment to get Guests to their destinations on time.

· Spirit is one of the top airlines for on-time performance, according to DOT statistics over the past several months.
· With the youngest planes in the U.S., Spirit has added 12 brand-new planes in the last six months to their Fit Fleet^® to get Guests where they are going safely and reliably.  Spirit consistently ranks as one of the most fuel-efficient airlines in the U.S.

*• Improving the Experience* – The commitment to improve every aspect of Guests’ journey based on feedback.

· All Flight Attendants now attend a robust inflight Guest Service Training Program developed in partnership with a world-class hospitality leader. This program will roll out to all of Spirit’s airport teams this summer, in a continued effort to better serve our 23 million Guests annually.

*• À La Smarte* – The commitment to give Guests more choices when it comes to how they fly and how they save.

· Spirit’s latest technology initiatives allow Guests to have more control over their booking, check-in and travel experience, including a mobile-friendly website, Spirit Check-In App, new airport kiosks and self bag tagging.
· This year, Spirit expanded its network to include Columbus, Ohio, Richmond, Va., Guayaquil, Ecuador, Cap-Haïtien, Haiti, and St. Croix, U.S. Virgin Islands, in addition to adding even more routes to some of the best vacation destinations in the world.  

*• Giving Spirit* – The commitment to give back to the communities where Spirit lives and works.   

· This year, Spirit has supported more than 100 charities and community organizations with countless flights and volunteer hours.

*About Thales Group: *
The people we all rely on to make the world go round – they rely on Thales. Our customers come to us with big ambitions: to make life better, to keep us safer. Combining a unique diversity of expertise, talents and cultures, our architects design and deliver extraordinary high technology solutions. Solutions that make tomorrow possible, today.  From the bottom of the oceans to the depth of space and cyberspace, we help our customers think smarter and act faster - mastering ever greater complexity and every decisive moment along the way. With 65,000 employees in 56 countries, Thales reported sales of $18 billion in 2017.

For more than 100 years, Thales has conducted significant research and development, manufacturing, and service capabilities in the U.S. Today, Thales is present in 13 states operating 23 different facilities.  Working closely with US customers and local partners, Thales is able to meet the most complex requirements for every operating environment.

*About Spirit Airlines: *
Spirit Airlines (NYSE:SAVE) is committed to offering the lowest total price to the places we fly, on average more than 30% lower than other airlines*. Our customers start with an unbundled Bare Fare^® and get Frill Control^® which allows them to pay only for the options they choose — like bags, seat assignments and refreshments — the things other airlines bake right into their ticket prices. We help people save money and travel more often, create new jobs and stimulate business growth in the communities we serve. Our Fit Fleet^® is the youngest and one of most fuel-efficient in the U.S. We operate more than 500 daily flights to 65 destinations in the U.S., Latin America and the Caribbean. Come save with us at spirit.com.

*Based on DOT data and verified by Campbell-Hill Aviation Group, LLC.

CONTACT: Spirit: Stephen Schuler
954-364-0231
Stephen.Schuler@spirit.com

Thales: Adam Kostecki
703-838-5645
adam.kostecki@us.thalesgroup.com Reported by GlobeNewswire 2 hours ago.

PITTSBURGH--(BUSINESS WIRE)--Dynamics Inc., an innovator in next-generation payment systems, today announced that the Dynamics Wallet Card™ has won Best of Show at Finovate Spring. The conference, held this week in Santa Clara, showcases cutting-edge banking and financial technology through a unique blend of short-form demos and key insights from thought-leaders. Best of Show winners were determined by the Finovate attendees who rated the more than 50 demoing companies on the basis of potential Reported by Business Wire 1 hour ago.

A research team has created an electrode for hydrogen evolution. A nickel-molybdenum (NiMo) catalyst is wrapped in a 'holey' graphene layer containing nanometer-sized holes. The fringes of the holes are chemically active sites, boosting hydrolysis by accelerating charge transfer and H atom adsorption. Meanwhile, graphene protects the NiMo core from dissolving. Through efficient hydrogen generation in acid solution using non-noble metals, the system potentially allows affordable green energy storage. Reported by Science Daily 40 minutes ago.

NEW YORK, May 11, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company," or AMBS), a US-based JLABS-alumnus biotechnology holding company, developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today provided a business update to the financial community regarding the business operations of the Company and its subsidiaries.Overview of Amarantus Operations

In April 2017, Amarantus Bioscience Holdings ("AMBS" or the "Company") made the strategic decision to house our various assets in individual subsidiaries to raise focused capital in order to move the assets forward. The Company formed wholly-owned subsidiaries Elto Pharma, Inc. to house intellectual property (IP) rights to Eltoprazine which is moving into Phase 2b clinical development for the treatment of Parkinson's disease levodopa dyskinesia (PD-LID) and MANF Therapeutics, Inc. to house IP rights to mesencephalic astrocyte-derived neurotrophic factor ("MANF") which is moving into IND-enabling studies for the treatment of orphan ophthalmological diseases. The formation of Elto Pharma and MANF Therapeutics added to the already established wholly-owned subsidiary Cutanogen Corporation which is developing Engineered Skin Substitute (ESS) initially for the treatment of life-threatening pediatric severe burns. Taken together, these three subsidiaries of AMBS are developing orphan therapeutic assets that are in areas of neurology, regenerative medicine and ophthalmology where competition is limited, and where each program has the potential to become 'standard of care' for multiple indications.

In addition, on April 6th, 2018, AMBSannounced that it reacquired rights to Alzheimer's Blood Diagnostic LymPro Test and MS diagnostic MSPrecise, and subsequently on May 4th, 2018 entered into an exclusive option agreement with Leipzig University to gain access to additional IP and data rights surrounding the use of LymPro Test with amyloid PET imaging for the diagnosis of Alzheimer's disease. The Company is evaluating the formation of a neuro-diagnostics subsidiary to raise capital to move those diagnostic assets forward. As a result, the four primary assets of the Company are being positioned to move forward independently within their subsidiary, attract executive talent, and raise capital on their own to advance the programs, with Amarantus' primary focus being on protecting and growing the value of the shares AMBS holds in each of those subsidiaries. As these opportunities mature, become further de-risked and gain traction in the market, AMBS will evaluate the return of capital to Amarantus shareholders to drive AMBS's value and reward shareholder loyalty.

As the Company continues to work on the financing plan for each subsidiary, one of the primary reasons for raising capital into the subsidiaries is to limit AMBS's need for dilutive capital on an ongoing basis at the parent level. Going forward, each subsidiary is being populated with key executives and product development teams that have the experience and skillsets to drive these programs towards milestones that will improve their individual value as they achieve FDA milestones with guidance of AMBS' Chief Regulatory Advisor Brian Harvey. The companies will in turn have greater demand for partnering or acquisition from larger organizations with distribution capabilities. The quality of the slate of Chief Medical Advisors (CMAs) recently appointed to Elto Pharma (Paula Trzepacz, MD), Cutanogen Corporation (Richard Kagan, MD) and LymPro (Michael Ropacki, PhD) speaks to the soundness of the scientific and medical approach to each of these programs, and gives AMBS confidence that each subsidiary will be able to attract additional expertise, as well as the capital necessary to advance the programs. We believe executing this strategy provides the best opportunity for shareholder value creation.

Capital Raising Strategy for AMBS

AMBS is focused on utilizing regulations created under the JOBS Act to raise equity capital that will allow it to complete its recapitalization plan and focus on the business of managing its portfolio. The Company is in active discussions with key advisors and investment banking firms to advance this effort. In March, the Company completed the Tender Exchange which restructured outstanding securities that previously inhibited the Company's ability to raise equity capital, and in April retained counsel experienced in negotiating with accounts payable (AP) creditors to complete the AP settlement requirements under the Tender Exchange agreement, thereby releasing the liens on the Company's assets. Going forward, the Company is looking at the next equity raise under the JOBS Act as the turning point that will allow it to emerge from the recapitalization phase and return to normal business operations.

Alzheimer's Blood Diagnostic LymPro Test Update

Amarantus continues to believe in LymPro. The feedback the Company received in 2015-16 surrounding the use of LymPro in clinical trials was quite positive as it related to the cell-cycle hypothesis of Alzheimer's that underpins LymPro, and the clinical data produced as of that time. However, prospective collaborators noted that what was missing from our initial dataset was the use of a reference standard that incorporated newly available biomarkers, such as PET imaging. In presenting final LP-002 LymPro data at the Alzheimer's Association International Conference (AAIC) in 2015, the Company showed equivalence between LymPro and the clinical diagnosis-only reference standard in distinguishing patients diagnosed with dementia of the Alzheimer's type from healthy controls, based on clinical diagnosis alone. Thereafter, Amarantus worked closely with Leipzig to design a clinical study that would overcome those previous shortcomings by evaluating LymPro's ability to discriminate patients with dementia of the Alzheimer's type from patients who suffer from other forms of dementia using clinical diagnosis in addition to various biomarkers, such as amyloid PET imaging. The Company is grateful to Leipzig for having financed the entirety of that study (LymPro PET 1), and for initiating a second, confirmatory study (LymPro PET 2) that is currently enrolling. For Amarantus shareholders, this means that while AMBS was unable to advance the LymPro asset over the last 3 years, LymPro was continuing to move forward at Leipzig and AMBS is now positioned to become the beneficiary of those efforts. A recent statement from Merck (below) in the New England Journal of Medicine conceded the widely held hypothesis of amyloid's causative role in Alzheimer's disease may itself be flawed, bringing even greater importance to the scientific hypotheses behind LymPro, which sit 'up-stream' to amyloid plaque:

"This suggests that once dementia is present, disease progression may be independent of A production or, alternatively, that the amyloid hypothesis of Alzheimer's disease may not be correct."

- N Engl J Med 2018; 378:1691-1703

Given the continued high failure rates in Alzheimer's clinical trials, major uncertainties emerging regarding the amyloid therapeutic hypothesis of Alzheimer's disease, and the wealth of scientific data continuing to emerge that supports the cell-cycle hypothesis of Alzheimer's disease (https://www.spandidos-publications.com/etm/15/1/103), the Company believes LymPro puts Amarantus squarely back in the center of emerging technologies that have the potential to make a significant impact in the development of new treatment paradigms for Alzheimer's. AMBS intends to bring in seasoned management to build a business around LymPro.

Elto Pharma Update

Based upon an independent 3rd party valuation of the PD-LID indication in the US and Europe alone, Eltoprazine is the most valuable asset in the Amarantus portfolio as measured by risk-adjusted net present value (rNPV), with a robust 9-figure valuation. This rNPV is primarily driven by the fact Eltoprazine:

· Is in Phase 2b clinical development, with strong initial Phase 2a data;
Is being developed to enter a growing market with little competition;
Is treating a significant orphan drug-designated patient population (180,000+ in the US alone);
Has recently approved competitive medicines in PD-LID that are beginning to demonstrate value to the payor community.

As a result, Amarantus is laser-focused on ensuring that Elto Pharma attracts long-term focused capital that will allow it to fulfill its initial mission to advance the PD-LID indication through Phase 2b. If successful, Elto Pharma could see secondary indications such as Agitation in Alzheimer's disease and Adult ADHD dramatically increase the program's rNPV as they re-enter mid-stage clinical development based on the strength of their initial Phase 2 data.

Based on this information, Elto Pharma is preparing to initiate a private round of financing, followed by preparations for a traditional initial public offering (IPO) that has seen comparable companies command valuations in the hundreds of millions. We believe that capital raising around Elto Pharma could drive the value of the Amarantus shares, based upon our then ownership position in that entity. The Company has begun working with domestic (NYSE or NASDAQ) and international advisors (Hong Kong, or others) to determine the best jurisdiction to list Elto Pharma. The Company intends to provide updates on Elto Pharma to Amarantus shareholders as progress is made.

Cutanogen Corporation Update

It is clear, based upon the data published in the Journal of Burn Care and Research in 2017, that Cutanogen's ESS has tremendous potential to dramatically improve the standard of care in the treatment of acute pediatric burns, as measured by a number of key trial endpoints:

1. Reducing mortality vs. historical control;
Reducing time to wound closure vs. historical control;
Improving function post-treatment vs. historical control.

Based upon the strength of the data seen to date, the Company believes Cutanogen is ready to move into a pivotal study to bring this life-saving orphan treatment to market, making pediatric burns the first indication for which Cutanogen will be seeking approval for ESS. The opportunity for ESS, however, expands far beyond the treatment of acute pediatric burns.

ESS is a cell & gene therapy skin platform technology that has a multitude of possible use cases in the medical field. Two examples of potential uses of this technology that have already been used in humans include:

1. Re-grafting/revision surgeries covering large body surface areas;
Giant Congenital Melanocytic Nevus management.

As Cutanogen builds out the commercial plan for ESS, and assesses the collective rNPV of each use case, it becomes clear that ESS could become a standard tool in acute treatment settings, but also in elective treatments where skin harvesting can be scheduled to meet a pre-defined timeline. Recent data published in Nature regarding the use of gene therapy on epidermal skin grafts for the treatment of an epidermolysis bullosa patient (https://www.nature.com/articles/nature24753) clearly points to the potential use of gene therapy with the ESS platform, which opens up the potential use of ESS to a wide range of rare pediatric skin diseases. Cutanogen has IP rights to the use of ESS in combination with gene therapy.

Beyond the use cases for ESS noted above, recent data published on improvements made to ESS (https://onlinelibrary.wiley.com/doi/full/10.1111/pcmr.12609) have added the potential to match the skin color of the graft to the skin color of the patient via the addition of melanocytes in the next generation version of the product (ESS 2.0). Consequently, the ESS 2.0 platform can expand beyond the treatment of acute catastrophic and rare pediatric conditions, and expand into cosmetic applications, significantly opening the market potential for this product. Taken together, the potential uses for the current ESS, ESS 2.0 and further generations of ESS have the potential to significantly drive the rNPV of the product based upon its fundamental scientific and medical characteristics.

What could further drive rNPV for ESS is the Rare Pediatric Disease Designation (RPDD) program at the FDA that provides incentives, in the form of Priority Review Vouchers (PRVs), to companies that develop treatments for rare diseases that primarily affect children. The Company believes ESS is likely to qualify for one or more RPDDs over time. As such, the key focus for Cutanogen is now on raising private financing so that it can prepare for its own IPO as a cell & gene therapy platform technology company that is moving into pivotal studies as a life-saving treatment option in a potential rare pediatric condition, for which few adequate treatment options, if any, exist.

MANF Therapeutics

MANF Therapeutics continues to amass a tremendous portfolio of intellectual property covering the use of MANF in the treatment of a range of disorders. While still in pre-clinical development, the next major step for this program is the appointment of a Chief Medical Advisor who can help finalize the selection of the initial indication for first-in-man studies with MANF, and drive the program towards the clinic. There is significant reason to believe that successful first-in-man studies with MANF could have a dramatic impact on the rNPV of the MANF asset, as positive efficacy in one indication likely increases the potential of a positive outcome in other, potentially larger, indications. Amarantus has continued to work with key groups, including the Snow Foundation focused on developing new treatments for Wolfram's Syndrome, to advance the science underpinning MANF so that upon proper capitalization this asset can be swiftly moved to complete IND-enabling studies in preparation for first-in-man. Amarantus continues to believe that MANF is potentially the most valuable asset in the Amarantus portfolio and the Company will continue to invest in the IP underpinning MANF until such time that MANF Therapeutics can independently finance its development. With potential disease-modifying applications in Glaucoma, Parkinson's disease, Alzheimer's disease, myocardial infarction and diabetes, human proof of concept with MANF in an orphan indication would significantly drive the rNPV for MANF by establishing a reasonable risk adjusted discount to its value in the event of success in these larger indications.

Summary

While certain risks remain as we complete the recapitalization of AMBS and the capital formation process for our subsidiaries, the Company has made tremendous progress in the last 6 months towards bringing these important scientific and medical breakthroughs back into development following a prolonged period of inactivity. The new members of the team have injected significant insight and energy to our efforts. Going forward, Amarantus is focused on completing the capitalization of the parent via the JOBS Act, privately capitalizing its subsidiaries, and then facilitating the advancements of our subsidiaries to build value for AMBS and its shareholders.

*About Elto Pharma, Inc.*

Elto Pharma, Inc. is developing eltoprazine, an oral small molecule 5HT1A/1B partial agonist in clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID), aggression in Alzheimer's disease and adult attention deficit hyperactivity disorder (adult ADHD). Eltoprazine has been evaluated in over 680 human subjects to date, was well-tolerated and showed promising efficacy results in both cognitive and movement disorders. Eltoprazine has received orphan drug designation (ODD) from the US FDA for the treatment of PD-LID.

Eltoprazine was originally developed by Solvay (now Abbvie) for aggression-related indications. The eltoprazine program was out-licensed to PsychoGenics, Inc. (PGI). PGI licensed eltoprazine to Amarantus in 2014 after a successful proof-of-concept trial in PD-LID.

In April 2017, Amarantus incorporated the wholly-owned subsidiary Elto Pharma, Inc. for the purpose of raising capital to finance the further clinical development of eltoprazine.

*About Cutanogen Corporation *

Engineered Skin Substitute (ESS) is a tissue-engineered skin prepared from autologous (patient's own) skin cells. It is a combination of cultured epithelium and a collagen-dermal fibroblast implant that produces a skin substitute which contains both epidermal and dermal components. This model has been shown in preclinical studies to generate a functional skin barrier. Most importantly, because ESS is composed of a patient's own cells, it is less likely to be rejected by the immune system of the patient, unlike porcine or cadaver grafts in which immune system rejection is a possibility. A non-GMP version ESS has been used in investigator-initiated and compassionate-use clinical study settings in over 150 human subjects, primarily pediatric patients, for the treatment of severe burns up to 95% of total body surface area. The non-GMP version has also been used in the treatment of two patients with Giant Congenital Melanocytic Nevi (GCMN).

In July 2015, Amarantus acquired Lonza Walkersville's wholly-owned subsidiary Cutanogen Corporation, the sole licensor of intellectual property rights to ESS from Cincinnati's Shriners Hospitals for Children and the University of Cincinnati. Cutanogen Corporation is a wholly-owned subsidiary of Amarantus.

*About MANF Therapeutics, Inc. *

MANF (mesencephalic-astrocyte-derived neurotrophic factor) is believed to have broad potential because it is a naturally-occurring protein produced by the body to reduce/prevent apoptosis (cell death) in response to injury or disease, via the unfolded protein response. By administering exogenously produced MANF the body, Amarantus is seeking to use a regenerative medicine approach to assist the body with higher quantities of MANF when needed. Amarantus is the frontrunner and primary holder of intellectual property around MANF, and is initially focusing on the development of MANF-based protein therapeutics.

In April 2017, Amarantus incorporated the wholly-owned subsidiary MANF Therapeutics, Inc. to focus on the preclinical and clinical development of MANF. MANF's lead indication is retinitis pigmentosa, and additional indications including Parkinson's disease, diabetes and Wolfram's syndrome are envisioned. Further applications for MANF may include Alzheimer's disease, traumatic brain injury, myocardial infarction, antibiotic-induced ototoxicity and certain other orphan diseases.

*About LymPro Test*

The Lymphocyte Proliferation Test (LymPro Test) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.

*About Amarantus Bioscience Holdings, Inc.*

Amarantus Bioscience Holdings (AMBS) is a JLABS alumnus biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. AMBS' wholly-owned subsidiary Elto Pharma, Inc. has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, Alzheimer's aggression and adult attention deficit hyperactivity disorder, commonly known as ADHD. AMBS acquired the rights to the Engineered Skin Substitute program, a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by AMBS' wholly-owned subsidiary Cutanogen Corporation. AMBS' wholly-owned subsidiary MANF Therapeutics, Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor ("MANF"). MANF Therapeutics, Inc. is developing MANF-based products as treatments for brain and ophthalmic disorders. MANF was discovered by the Company's Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS' proprietary discovery engine PhenoGuard. The Company also re-acquired rights to the Alzheimer's blood diagnostic LymPro Test, MSPrecise and NuroPro.

For further information please visit www.Amarantus.com, or connect with the Amarantus on Facebook, LinkedIn, Twitter and Google+.

*Amarantus Investor and Media Contact:*

Howard Gostfrand

American Capital Ventures, Inc.

Office: 305-918-7000

Email: hg@amcapventures.com

Source: Amarantus Bioscience Holdings, Inc. Reported by GlobeNewswire 1 hour ago.

Free social communications app and digital bulletin board for mobile devices connects caregivers to provide better care.

VANCOUVER, B.C. (PRWEB) May 11, 2018

Blue Willow Systems, a leading provider of cloud-based e-call systems for senior resident communities, announces the next step in the evolution of senior communities’ communications with Blue Willow Chat™, a new free mobile and desktop app that enables senior living staff to communicate with each other securely and easily. With two new interactive features, Chat and Announcements, Blue Willow Chat™ improves communications and increases real-time connectivity for both staff and management utilizing mobile devices, while improving caregiver responsiveness and patient care.

“Blue Willow Chat provides the first step in enhancing community communications and quality care at zero cost,” said Bob Bailey, CEO, Blue Willow Systems. “We are bringing the ease and familiarity of social media and instant messaging right to caregivers’ hands on the mobile devices they are most familiar with – enabling them to quickly and securely connect with each other and their managers, and ultimately provide more responsive care to seniors. All you have to do is download the Blue Willow Chat™ app!”

Blue Willow Chat enables effortless communication among staff members across both desktop and mobile devices. It replaces the bulky, unreliable walkie-talkies of the past by allowing care staff to securely message each other on their own smartphones or other mobile devices. For administrators and management, Blue Willow Chat’s web desktop easily connects and communicates with mobile staff, ensuring they are informed of activities instantly throughout the community.

Blue Willow Chat’s innovative Announcements feature delivers a digital bulletin board that allows operators and management to post event notices and important information. Instead of posting information by pinning papers to a single board in a community which can be easily missed by many, Announcements delivers information immediately in a familiar format. A community’s entire staff can quickly be notified by pushing information to mobile phones, tablets and desktop computers. The Announcements feature also gives management full visibility into exactly which staff members have viewed each announcement.

Learn more about Blue Willow Chat, and the entire Blue Willow Platform at Argentum 2018, May 14 – 16, 2018 in San Diego, CA. Visit Blue Willow at booth #123 for a demo.

About Blue Willow Systems
Blue Willow Systems is a next generation SaaS resident safety platform that automatically detects falls with a patented algorithm, elegantly manages resident wandering with customized geofencing, analyzes real-time resident and staff activity, and automatically sends event alerts to both mobile and desktop devices. Blue Willow Systems provides sophisticated incident and trend reports allowing operators to deliver better care, reduce overhead, manage staff workflow and mitigate risk, resulting in increased profitability, staff effectiveness, and resident and family satisfaction. Reported by PRWeb 43 minutes ago.

New OpenRack and OpenSled infrastructure will be shown representing a significant step in the evolution of OCP’s CG-OpenRack-19 specification.

SAN JOSE, Calif. (PRWEB) May 11, 2018

ADLINK, a leading provider of telecom equipment and Plantinum member of the Open Compute Project (OCP), will be featuring carrier grade CG-OpenRack-19 solutions at the Big Communication Event in Booth B419 on May 14-16 in Austin, TX. These solutions include Multi-access Edge Compute solutions from multiple OCP partners and suppliers.

The Big Communications Event (BCE) is the communication industry's meeting point to discuss the major changes affecting its future. BCE brings telecom experts from around the globe. The conference and expo covers the industry's most pressing topics including automation, edge computing, intent-based networking, artificial intelligence, cloud-native software, advanced security strategies and 5G networks.

ADLINK and its partners have developed networking and communications platforms that enable Multi-access Edge Computing and cloud architectures for telecom operators and data centers. ADLINK’s Open Compute Carrier-grade Edge Reference Architecture (OCCERA) and OCP Solutions address the requirements for low-latency, high-bandwidth and compute-intensive applications driven by the needs of security, deep packet inspection (DPI), edge computing, virtual network functions, 5G evolution and other revenue producing solutions for operators.

At BCE, ADLINK, and partners nVent and Radisys will jointly showcase OCP-ACCEPTED™ OpenRack and OpenSled configurations that enable openstack resources to easily power virtualized applications at the edge. These specifications offer telecom data center operators the benefits of open platform standards combined with the required carrier-grade and environmental enhancements for edge computing in telecom data center environments. The open system approach drives innovation in the market and allows operators to avoid vendor lock-in that comes with propriety solutions. In addition, the multi-vendor solution offers seamless support across sales and integration cycles.

“Telecom operators are increasingly looking for improved technologies that ease implementaton and lower costs for Edge and 5G-based solutions. ADLINK and our OCP partners are meeting this need by delivering next generation equipment needed to meet the rigorous OCP-ACCEPTED standards.” Says Jeff Sharpe, ADLINK Director of Product Strategy for Networking and Communications. “We have been working with the OCP committee since 2012 and are very excited to see carriers deploying new equipment based on the standards. The migration to standards based equipment is allowing carriers to increase their network reliability with vendor-agnostic equipment while simultaneously lowering their costs”. Sharpe will also be participating in a panel discussion on May 16 entitled “Converting Central Offices to Datacenters” which will address the major challenges and key benefits for this industry wide initiative.
For more information on ADLINK’s OCP-ACCEPTED OCCERA platform, please visit our website.

For more information on nVent Electric’s CG-Openrack-19 capability, please visit their website.

ABOUT ADLINK
ADLINK Technology is a global leader of Edge Computing with a mission to reduce the complexity of building IIoT systems. Through a full range of offerings including embedded building blocks, intelligent computing platforms, fully featured edge platforms, data connectivity and extraction devices, secure software for data movement and micro services, ADLINK provides complete IIoT solutions serving a large customer base across industrial automation, networking & communications, healthcare, infotainment & retail, transportation, and government & defense industries.

ADLINK is a Premier Member of the Intel® Internet of Things Solutions Alliance and Intel® Network Builders, has a strategic partnership with NVIDIA to bring AI to the Edge, and is active in several standards organizations and interoperability initiatives, including PCI Industrial Computer Manufacturers Group (PICMG), Standardization Group for Embedded Technologies (SGeT), Open Fog Consortium, European Telecommunications Standards Institute (ETSI), Open Compute Project (OCP), Eclipse IoT, and ROS-Industrial Consortium for robotics.

ADLINK products are available in over 40 countries across five continents with a worldwide distribution network. ADLINK is ISO-9001, ISO-14001, ISO-13485 and TL9000 certified and is publicly traded on the TAIEX Taiwan Stock Exchange (stock code: 6166).

ABOUT NVENT Electric
nVent Electric plc, (“nVent”) with a principal office in London, England, and U.S. management office in Minneapolis, Minn., is a global leader of inventive electrical solutions that connect and protect customers by creating safer systems to ensure a more secure world. The nearly 9,000 employees worldwide design, manufacture and distribute electrical enclosures, electric heat tracing solutions, complete heat management systems, and electrical and fastening solutions. In 2018, nVent became an independent, publicly traded company (NYSE: NVT) after separating from Pentair plc (“Pentair”). Its robust portfolio of leading electrical product brands dates back more than 100 years and includes nVent CADDY, ERICO, HOFFMAN, RAYCHEM, SCHROFF and TRACER.

ABOUT Radisys
Radisys (NASDAQ: RSYS), a global leader in open telecom solutions, enables service providers to drive disruption with new open architecture business models. Radisys’ innovative disaggregated and virtualized enabling technology solutions leverage open reference architectures and standards, combined with open software and hardware to power business transformation for the telecom industry, while its world-class services organization delivers systems integration expertise necessary to solve communications and content providers’ complex deployment challenges. For more information, visit http://www.Radisys.com.

Intel and Xeon are trademarks of Intel Corporation in the U.S. and other countries. Radisys® is a registered trademark of Radisys Reported by PRWeb 43 minutes ago.

VANCOUVER, British Columbia and LONDON, May 11, 2018 (GLOBE NEWSWIRE) -- *BTL GROUP LTD.* (TSX Venture:BTL) (“*BTL*” or the “*Company*”) is pleased to announce that it will be demonstrating its Interbit platform in public for the first time, next week, at the Consensus blockchain conference in New York. BTL’s booth is number 133 and its exhibit will allow developers to interact with the platform and build applications on Interbit blockchains.  Furthermore, the first third party blockchain application built on Interbit will also be unveiled at Consensus. Interbit is the Company’s token free, next generation blockchain platform, that was made available on April 23, 2018 for testing and feedback (Interbit can be accessed and downloaded from the link https://interbit.io/). The platform provides a more secure environment for computing, ensures privacy of data, and via its unique “chain joining” capability, multiple blockchains can be used to build applications that are faster, scalable, and more resilient.

TruckLovely is the third party Interbit blockchain based application that will be unveiled at Consensus.  It is a truck routing application that streamlines logistics for companies and will benefit from the inherent uptime that Interbit provides, meaning companies using the application will not suffer from intermittent connectivity issues. Commercialisation of the TruckLovely application is expected later in 2018 when it will be available to purchase via BTL’s Interbit store.

“Blockchain is most commonly associated with cryptocurrency, but it has so many more potential real-world applications,” says Tom Thompson, Chief Technology Officer of BTL. “The TruckLovely app running on our Interbit platform brings blockchain out of the virtual world and uses it to deliver tangible goods and services to bricks and mortar businesses.”

BTL is also a sponsor at the Consensus Building Blocks Hackathon, being held at New York’s Microsoft Tech Centre, where circa 250 developers will be competing to win prize money for developing the best blockchain application. BTL is challenging developers to build a social media application with the functionality to delete data and is offering a reward of $5,001 to the winner.

Consensus is expected to attract 4,500 developers and business leaders from around the world.

*ABOUT BTL™ AND INTERBIT™*

Listed on the TSX Venture Exchange (TSX Venture:BTL) and operating from both Canada and the UK with offices in Vancouver, Calgary and London, BTL is a technology platform provider that owns Interbit, a next generation blockchain platform which enables business applications to be built quickly, easily and securely.

Interbit can be licensed by developers and businesses who can build and share their own applications in a trusted ecosystem, allowing them to embrace new revenue generating opportunities. Interbit meets the speed, scale and privacy that older generations of blockchain technology cannot achieve by using chain joining technology to connect multiple blockchains. It offers a simpler, more secure, new way of computing.

Website: www.btl.co & www.interbit.io
Twitter: https://twitter.com/blockchainltd & https://twitter.com/interbit_
Videos: https://youtu.be/YFOH0YEHLak & https://youtu.be/eWI-0AXaZgc

For further information please contact:

*Dominic McCann, CEO*
Phone: +1 855 256 5246
Email: dominic@btl.co

Certain statements in this release are forward-looking statements, which include further development of BTL’s business relationships and business and the timing, development and success of BTL’s technologies, BTL’s products, products built on BTL’s technologies, and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as “may”, “expect”, “estimate”, “anticipate”, “intend”, “believe” and “continue” or the negative thereof or similar variations. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, estimates, forecasts, projections and other forward-looking statements will not occur. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, the development of competitive technologies, the marketplace acceptance of BTL’s technologies and products, as well as those risk factors discussed or referred to in BTL's annual Management's Discussion and Analysis for the year ended December 31, 2017 available at www.sedar.com, many of which are beyond the control of BTL. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

The forward-looking statements contained in this press release are made as of the date of this press release.  Except as required by law, BTL disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Additionally, BTL undertakes no obligation to comment on the expectations of, or statements made by, third parties in respect of the matters discussed above.

*Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.* Reported by GlobeNewswire 37 minutes ago.

Classic cars are a solid investment of late, with rare and loved classics fetching millions at auction. For anyone who’s not already a millionaire, though, that’s inaccessible. Luckily, analysts Cap HPI has created another roundup of ones to watch on the used market at a lower price point. Here are the latest future classics, according to Cap HPI.

From the Renault Twizy to the Suzuki Jimny, here are some surprising cars that should make good investment buys

Classic cars can be a solid investment, with rare and loved classics fetching millions at auction. 

But you don't have to sell out vast sums to buy a used car that could appreciate in value. We've asked the analysts at Cap HPI to pick out some affordable cars that could become future classics.

-The most affordable future classics -

*Renault Twizy*

One of the early electric vehicles, the oddball Twizy has been in production since 2012 and is still being made today. 

You’d think that would depress its classic potential, but its low production volume, way-out-there looks, 50mph top speed and relatively tame 62-mile range helped to make the Twizy something of an acquired taste.

They’re quite hard to find — there’s only one on PistonHeads — but prices start from £3500 upwards. 

*Find out more: read our Renault Twizy review here*

*Renault Avantime*

Another French fancy, the Avantime is the only three-door MPV produced to date. 

In its time, that fact and a few packaging issues put buyers off, even though the arthouse styling caught the eye. Seventeen years later, the car's scarcity adds to its appeal and the Avantime is still bold and dynamic in appearance.

Want one? Well, they’re scarce and there's none available on PistonHeads (an equally kooky Vel Satis is available, mind). But when they come up, expect to pay between £4000 and £10,000, depending on condition. 

*Find out more: Fabulous failure - the Renault Avantime*

*Alfa Romeo Brera*

Few will disagree that the Brera is one of the prettiest cars to come out of Turin. 

Relative rarity caused by the car’s somewhat lukewarm performance at launch offset the striking looks, so the punchier 3.2-litre V6 attracts the biggest premium. The Vauxhall-engined diesel munched through cambelts relatively quickly, so well-looked-after examples can represent a bargain.

Prices vary, with leggy examples less than £5000 but clean sub-75,000-miles cars approaching £10,000. Take a look at the Breras currently for sale on PistonHeads here.

*Find out more: Alfa Romeo Brera | Used Car Buying Guide*

*Peugeot RCZ*

Peugeot’s answer to the Audi TT is no more and, with no replacement planned, demand is rising. 

Poor promotion led to its axing after just five years on sale, but not after it gained accolades for confirming the French brand’s renaissance. Handling, styling and pricing were all promising, but it couldn’t be saved.

That’s a win for used buyers — £6000 will buy an early model with less than 90,000 miles on the clock, while prices max out at £15,000 for low-mileage late models in the PistonHeads classifieds.

*Find out more: Peugeot RCZ | Used Car Buying Guide*

*Mk5 Volkswagen Golf GTI, R32*

Prices for the first and second generation Golf GTI have been rising for a number of years now, but the unloved, lukewarm third and fourth-generation Golf GTIs have been skipped. 

Values of the R32 version of the fourth-generation Golf have already started taking off, so all eyes turn to the hot Mk5 variants. That GTI was something of a renaissance for the hot hatch icon, while the VR6-engined R32 is an altogether rarer prospect. 

£4000 gets a high-mileage Mk5 GTI, while R32s start at around £2000 on top of this. The best buys are unmodified, though, so find a less used example for the best gains. 

*Find out more: Volkswagen Golf GTI | Used Car Buying Guide*

*986 Porsche Boxster*

Few cars pick up value like a classic Porsche, but the big earners tend to be expensive in the first place. 

The Boxster, however, is Porsche’s most affordable modern model and Cap HPI predicts that the first-generation Boxster, the 986, will have its moment shortly. Look for a clean, lower-mileage model and the sub-£10,000 you spend could grow.

Rock-bottom examples start from less than £4000, but it’s not until £5000 that the miles creep below 100k and not until around £7000 that you can get the more desirable 3.2-litre cars. Take a look at the selection available on PistonHeads.

*Find out more: Used car buying guide: Porsche Boxster from £3000*

*Suzuki Jimny*

A new Jimny will be launched later this year, so the current-generation Jimny, as tough off road as it is diminutive in stature, is experiencing something of a resurgence in popularity. 

Sure, its on-road manners leave a fair amount to be desired, but with cult appeal it's definitely one to watch. It’s been in production since 1998, so there's a Jimny for most budgets. 

£2000 buys a clean enough example with less than 80,000 miles. Take a look through the Jimnys available on PistonHeads classifieds here.

*Read more: Next Suzuki Jimny to be revealed later this year before sales kick off in 2019*

*Toyota MR2*

Reliable? Check. Fun to drive? Check. Scarce? Increasingly, yes. That’s a holy trinity when it comes to appreciating modern classics and the Toyota MR2 is no different.

Naturally, the first-generation is most scarce, but will bring the biggest rewards: prices are already on the rise. Those on a budget should seek out a third-generation car, although they will have a longer wait before considerable appreciation sets in. 

Although tempting, £2000 examples won’t have the same investment potential as more-cared-for £4000 cars. Browse all three generations here.

*Read more: Toyota MR2 | Used Car Buying Guide* Reported by Autocar 5 minutes ago.

Volkswagen's new Touareg SUV is so clever it can see in the dark. Night Vision is part of a new suite of technologies on the new generation model which also includes a world premier for the Innovation Cockpit which will gradually be rolled out through the automaker's other model ranges. Reported by Just-Auto 11 minutes ago.

Using Florida's VW Funds for Large Engine Clean Diesel Upgrades Will Yield More Clean Air for the Settlement Dollar

TALLAHASSEE, May 11, 2018 (GLOBE NEWSWIRE) -- Florida is set to recieve a $166.3 million infusion of cash through the Volkswagen (VW) Environmental Mitigation Trust. The VW settlement is designed to fund projects that reduce emissions of nitrogen oxides (NOx).

Through 5 p.m. today, Florida's citizens have the opportunity to chime in on how these funds should be spent.

"According to the latest NOx emissions inventory, the largest sources of NOx in Florida are engines that power heavy-duty vehicles and equipment. A strategy that replaces or upgrades these large engines is one that offers Florida the greatest opportunity for NOx mitigation," said Allen Schaeffer, executive director of the Diesel Technology Forum. "Upgrading these oldest and highest-emitting engines and equipment with the newest generation of advanced diesel engines will yield 17.5 times the emissions reductions as allocating the funds toward electric school bus purchases. That translates to dramatic environmental and public health benefits for the most people in the shortest amount of time."

For Florida's $166.3 million, the state could replace 119 of the oldest work boats plying Florida's coastlines and ports. This would reduce 3.5 MILLION POUNDS OF NOx EMISSIONS. Or, the state could invest those funds in just 189 electric buses, and reduce less than 200,000 pounds of NOx.

"Using the funds to buy new electric buses would no doubt be a benefit to those few who got to ride a new bus, but not to everyone else," continued Schaeffer. "Why? Compared to working engines and equipment, school buses have low annual miles, may not operate all year round, and most importantly contribute very little to Florida's emissions inventory. Electric buses would cost a lot of money, and yet are among the LEAST cost effective ways to use Florida's funds.

"Getting rid of the oldest and largest and dirtiest diesel engines will yield the most clean air for Floridians, and the clean diesel option will yield those NOx reductions more quickly and at a lower cost. For the most clean air for the settlement dollar, large engine diesel upgrades are the way to go."

The Forum's formal comments to Governor Scott and the Florida Department of Environmental Protection may be found here. Visit https://www.dieselforum.org/vwfund for more information about best options for Volkswagen settlement funds in Florida and other states.

# # #

The Diesel Technology Forum is a non-profit organization dedicated to raising awareness about the importance of diesel engines, fuel and technology. Forum members are leaders in clean diesel technology and represent the three key elements of the modern clean-diesel system: advanced engines, vehicles and equipment, cleaner diesel fuel and emissions-control systems. For more information visit www.dieselforum.org.

*Attachments*

· Clean Diesel Tugboat Engine Upgrades
· Clean Diesel Locomotive Engine Upgrades

CONTACT: Sarah Dirndorfer
Diesel Technology Forum
301-668-7230
sdirndorfer@dieselforum.org Reported by GlobeNewswire 7 minutes ago.

Townhouse Management Company to revitalize Memphis, Acquires the City's Tallest Building and Two Adjacent Full City Blocks next to City Hall Campus

(PRWEB) May 11, 2018

THM Memphis Acquisitions LLC (“THM”), an affiliate of New York City based Townhouse Management Company, has acquired the iconic 37 story, 800,000 square foot office tower at 100 North Main Street, which is Memphis’ tallest building.    

Situated on over an acre of land, 100 North Main is on the National Register of Historic Places. It was constructed in 1965 as the AP Bank Building. The stately building has a rotating restaurant, its own Wikipedia page and floor plates of over 16,000sf.

THM, which had been the building’s mortgage holder, may convert the building into a 4-1/2 Star 600 Guest Room Luxury Hotel with 110 apartments, a 7500 square foot lobby, two restaurants, a spa, 20,000 square feet of retail space and ballrooms totaling nearly 75,000sf.

THM also announced that it has acquired seven parcels of land that are contiguous with 100 North Main consisting of the four buildings located at 82-88 North Main, an empty lot formerly a dog walking area, and 2 parking lots immediately to the north and east of those buildings. Two 30 story office towers totaling over 500,000sf are planned as is a new 467,000sf parking garage for over 1200 cars. These acquisitions have cost $12 million to date.

THM is also in contract for $4 million to buy the 104,000 square foot vacant office building located at 147 Jefferson Avenue and the vacant parcel of land located just to the south 60 South 2nd Street.

In a prepared statement, Arlene Maidman, THM’s Executive Co-Chair said, “We are enlivened by the spirit of cooperation, fairness and commitment shown to all our team members by The City of Memphis and its people.

“Mayor Strickland, Doug McGowen, Jennifer Oswalt, Kevin Kane and many others have been outstanding and highly professional leaders in working with us during the RFP process that resulted in the agreement (announced by the City of Memphis yesterday) to exclusively negotiate with the THM and Loews Hotels & Co for tax incentive financing to develop Memphis’ official Convention Center Hotel.

“THM is looking forward to being a leading force in the revitalization of Downtown Memphis and intends to re-develop the three contiguous acres as a single mixed-use project, consisting of more than two million square feet of hospitality, extended stay, retail, residential, commercial and parking uses.

“We could not have chosen a better, more dynamic, prolific, and qualified partner. Loews Hotels comes with tremendous bandwidth and expertise in the ownership, management, development and leadership of Convention Center Hotels, having developed many such hotels across the country.”

THM is an affiliate of New York City-based Townhouse Management Company, a third generation family real estate owner, manager and developer which acquires, develops, and manages properties throughout the New York metropolitan area.

Contact:
Harry Zlokower
(212) 863-4120
harry(at)zlokower(dot)com Reported by PRWeb 5 hours ago.

PRESS RELEASE: REGULATED INFORMATION
11 May 2018, 17:40 CEST

                                                          

*Results of the annual shareholders' meeting held on 11 May 2018**
*

*Mechelen, Belgium, 11 May 2018* - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), held its annual shareholders' meeting in Mechelen today. 
The shareholders approved all items on the agenda. All documents relating to the annual shareholders' meeting can be consulted on the website of the Company.

*--- END ---*

*More information: *

Renate Degrave
Manager Corporate Communications & Investor Relations
e-mail    rdegrave@biocartis.com
tel         +32 15 631 729
mobile   +32 471 53 60 64

*About Biocartis *

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla(TM) platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis offers fourteen oncology tests and two infectious disease tests in Europe. More information: www.biocartis.com. Press Photo Library available here. Follow us on Twitter: @Biocartis_.

Biocartis and Idylla(TM) are registered trademarks in Europe, the United States and other countries. Biocartis trademark and logo and Idylla(TM) trademark and logo are used trademarks belonging to Biocartis. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.

*Forward-looking statements*

This press release may contain forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements speak only as of the date of this press release. Biocartis expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release, except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements. Reported by GlobeNewswire 5 hours ago.

SACRAMENTO, Calif., May 11, 2018 (GLOBE NEWSWIRE) -- The Association of California Water Agencies (ACWA) has announced the names of five undergraduate students selected to receive varying awards for the 2018-’19 academic year under ACWA’s undergraduate scholarship programs. The awards were announced during presentations at ACWA’s 2018 Spring Conference & Exhibition in Sacramento May 8-11, where 1,561 local water officials gathered for programs and panel discussions on a variety of key water issues.“For more than half a century ACWA has been investing in students who will become California’s future water leaders,” said ACWA President Brent Hastey. “I am very proud to be part of an organization that supports California’s water industry in such a meaningful way. Congratulations to all of our scholarship winners.”

This year’s undergraduate scholarship recipients were selected by the ACWA Communications Committee Awards & Scholarships Subcommittee, which conducted a thorough evaluation of the students’ qualifications, as well as letters of recommendation and personal essays. The subcommittee is chaired by Glen-Colusa Irrigation District Personnel and Communications Director Cynthia Davis.

The students and the programs for which they were awarded are:

*ACWA Scholarship ($3,500 each)*

· *Ashley Green*, an Environmental Engineering student at California Polytechnic State University, San Luis Obispo.
· *Benjamin Clemons*, a Chemistry/Environmental Engineering student at UC Berkeley.             

*Clair A. Hill Scholarship ($5,000)*

· *Rebecca Burke*, an Environmental Resources Engineering student at Humboldt State University

San Diego County Water Authority, the winner of the 2017 Clair A. Hill Water Agency Award for Excellence, presented the scholarship to Burke during a luncheon on Thursday, May 10. This scholarship is sponsored by Jacobs.

*Ted and Nancy Way Scholarship for the Next Generation of Water Leaders ($5,000 each)*

This year marks the first round of awards under this program, which was established in 2017 by Ted and Nancy Way. Mr. Way is a long-term water leader and former member of ACWA’s Water Quality Committee.

This year’s recipients are:

· *Chloe Fowler*, an Agricultural Communications student at California Polytechnic State University, San Luis Obispo.
· *Elizabeth Riggall*, an Environmental Policy and Planning and Public Health student at UC Davis.

The recipient of ACWA’s graduate scholarship – the Stephen K. Hall Water Law and Policy Scholarship – for the 2018-’19 academic year will be announced this fall during ACWA’s 2018 Fall Conference & Exhibition in San Diego.

For more information about ACWA’s scholarships, please visit www.acwa.com/about/scholarships.

ACWA is a statewide association of public agencies whose more than 440 members are responsible for about 90% of the water delivered in California. For more information, visit www.acwa.com

*Contact:* Heather Engel, Director of Communications | (916) 441-4545 | C (760) 217-0627 Reported by GlobeNewswire 5 hours ago.

Jimmy Kimmel asked several celebs to read texts from their mothers in honor of Mother's Day, and it was as heartwarming as it was hilarious! Anna Faris's proud mom, for example, called her "the greatest actress of [her] generation," but admitted she still hoped the Mom star would eventually "transition into dramatic work." Ha! Watch the funny [...] Reported by Perez Hilton 4 hours ago.

SACRAMENTO, Calif., May 11, 2018 (GLOBE NEWSWIRE) -- United Launch Alliance (ULA) has selected Aerojet Rocketdyne’s RL10 rocket engine to power the upper stage that will fly atop ULA’s new Vulcan Centaur launch vehicle. The selection came as part of a long-term agreement between the two companies that calls for Aerojet Rocketdyne to provide RL10 upper-stage rocket engines to support ULA’s current and future launch vehicles.“Having the RL10 selected to support Vulcan Centaur means ULA and Aerojet Rocketdyne will continue working together to extend our track record of mission success well into the future,” said Aerojet Rocketdyne CEO and President Eileen Drake. “We look forward to working alongside the outstanding team at ULA to make the Vulcan Centaur rocket a reality in order to provide reliable and affordable access to space for our nation.”“ULA and Aerojet Rocketdyne have a long and successful history together that began with the first flight of our Atlas and Delta rockets in the 1960s,” said Tory Bruno, ULA president and CEO. “We could not be more pleased to have selected the proven and reliable RL10 to power our Vulcan Centaur upper stage.”

While some terms of the agreement remain confidential, it includes a long-term commitment by ULA to use RL10 engines on the company’s current Centaur and next-generation Centaur upper stages for future ULA procurements, as well as a joint commitment to invest in next-generation engine development.“The agreement also defines a path forward that will enable us to develop the next generation of RL10 engines that will incorporate additive manufacturing and other advanced technologies to make the engine more affordable while retaining its proven performance and reliability,” continued Drake.Last year, Aerojet Rocketdyne successfully hot-fire tested a full-scale, additively manufactured thrust chamber assembly for the RL10 that was built from a copper alloy using a 3-D printing technique known as selective laser melting or SLM. Since then, the company has been working to develop and qualify a variety of components that take advantage of SLM technology.“With nearly 500 engines flown in space over the last five decades, the RL10 has earned an unmatched reputation in the industry,” said Drake. “We will continue to build this proud legacy by supporting ULA’s new Vulcan Centaur rocket for many years to come.”

Aerojet Rocketdyne, a subsidiary of Aerojet Rocketdyne Holdings, Inc. (NYSE:AJRD), is an innovative company delivering solutions that create value for its customers in the aerospace and defense markets. The company is a world-recognized aerospace and defense leader that provides propulsion and energetics to the space, missile defense and strategic systems, tactical systems and armaments areas, in support of domestic and international markets. Additional information about Aerojet Rocketdyne can be obtained by visiting our websites at www.Rocket.com and www.AerojetRocketdyne.com.

*Contact:
Todd McConnell, Aerojet Rocketdyne, 561-882-5395*
todd.mcconnell@rocket.com
*Mary Engola, Aerojet Rocketdyne, 571-289-1371*
mary.engola@rocket.com

  Reported by GlobeNewswire 5 hours ago.